Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718249 | 0.87 | ALDH1A1 (0.38) | HTTCNR2HPGDTSHRNPSR1 | |
| SCHEMBL371239 | 0.81 | HTT (0.48) | HTTCNR2HPGDTSHRNPSR1 | |
| SCHEMBL13283814 | 0.80 | HTT (0.47) | HTTCNR2HPGDTSHRNPSR1 | |
| SCHEMBL28766107 | 0.78 | TSHR (0.38) | HTTTSHRPOLBALDH1A1HSD17B10 | |
| SCHEMBL435702 | 0.78 | ALDH1A1 (0.36) | HTTCNR2HPGDTSHRPOLB | |
| SCHEMBL14676577 | 0.74 | HPGD (0.56) | HTTCNR2HPGDTSHRNPSR1 | |
| SCHEMBL9199739 | 0.70 | HTT (0.50) | HTTCNR2HPGDTSHRNPSR1 | |
| SCHEMBL18255993 | 0.70 | P2RX7 (0.49) | HTTALDH1A1KMT2AMEN1ALOX15 | |
| SCHEMBL11370548 | 0.70 | PTGS2 (0.40) | HTTALDH1A1LMNAPTGS1 | |
| SCHEMBL15248902 | 0.70 | PTGS2 (0.44) | PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635587-B1 | 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO LTD (CN) | 2017-02-15 | — | — | EP | disclosed |
| EP-2635587-B1 | 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO LTD (CN) | 2017-02-15 | — | — | EP | disclosed |
| US-9540396-B2 | 6-arylamino pyridone carboxamide as MEK inhibitors | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-10 | — | — | US | disclosed |
| US-9540396-B2 | 6-arylamino pyridone carboxamide as MEK inhibitors | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-10 | — | — | US | disclosed |
| US-9540396-B2 | 6-arylamino pyridone carboxamide as MEK inhibitors | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-10 | — | — | US | disclosed |
| US-20140080804-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| US-20140080804-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| US-20140080804-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| EP-2635587-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | Centaurus Biopharma Co., Ltd. (CN) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012059041-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012059041-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080804-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | MAP3K6, MAP3K1, MAP3K21 | HTT 3488/4885CNR2 1703/4885HPGD 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.